Clinical Pharmacokinetics of Pravastatin

Clinical Pharmacokinetics

Volumn 27, Issue 2, 1994, Pages 94-103

  Quion, Jun Anthony V ^a   Jones, Peter H ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; ANTILIPEMIC AGENT; COLESTYRAMINE; CYCLOSPORIN; DRUG METABOLITE; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYL GROUP; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; NICOTINIC ACID; PROPRANOLOL; SIMVASTATIN;

BLOOD; DRUG EFFECT; DRUG INTERACTION; HUMAN; INTESTINE ABSORPTION; REVIEW; ACTIVE TRANSPORT; AREA UNDER THE CURVE; BLOOD BRAIN BARRIER; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG ABSORPTION; DRUG ADMINISTRATION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG LIVER LEVEL; DRUG PROTEIN BINDING; DRUG STRUCTURE; FEMALE; HYDROPHILICITY; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; LIVER; MALE; META ANALYSIS; MYOPATHY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; URINARY EXCRETION;

DRUG INTERACTIONS; HUMAN; INTESTINAL ABSORPTION; LIPOPROTEINS, LDL CHOLESTEROL; PRAVASTATIN;

EID: 0028168962     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.2165/00003088-199427020-00002     Document Type: Review

References (54)

1. Heterozygous familial hypercholesterolemia and the relationship between plasma lipids, lipoproteinemias, clinical manifestations and ischemic heart disease in men and women
2. Risks of ischaemic heart-disease in familial hyperlipoproteinaemic states
3. The cholesterol facts: a summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease. A joint statement by the American Heart Association and the National Heart, Lung, and Blood Institute
4. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease
5. The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering
6. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study
7. Effects of therapy with cholestyramine in progression of coronary arteriosclerosis: Results of the NHLBI Type II Coronary Intervention Study
8. The influence of changes in lipid values induced by cholestyramine and diet on progression of coronary artery disease: Results of the NHLBI Type II Coronary Intervention Study
9. Fifteen year mortality in Coronary Drug Project patients: long term benefits with niacin
10. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts
11. Regression of coronary artery disease as a result of intensive lipid lowering therapy in men with high levels of apolipoprotein B
12. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)
13. HMG-CoA reductase inhibitors for treatment of hypercholesterolemia
14. Current approaches to drug therapy for the hypercholesterolemic patient
15. Efficacy and long-term adverse effect pattern of lovastatin
16. Lovastatin and simvastatin prevention studies
17. Long-term experience with pravastatin in clinical research trials
18. ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinum
19. 3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: a new class of cholesterol-lowering agents
20. Clinical implications of new drugs for lowering plasma cholesterol concentrations
21. Discovery, biochemistry and biology of lovastatin
22. Pravastatin: a hydrophilic inhibitor of cholesterol synthesis
23. A quarter century of drug treatment of dyslipoproteinemia with a focus on the new HMG-CoA reductase inhibitor fluvastatin
24. The effect of CS-514, an inhibitor of HMG-CoA reductase, on serum lipids in healthy volunteers
25. The effect of CS-514 on serum lipids and apolipoproteins in hypercholesterolemic subjects
26. Once-daily pravastatin in patients with primary hypercholesterolemia: a dose-response study
27. Efficacy and safety of pravastatin in patients with primary hypercholesterolemia
28. Determination of pravastatin sodium and its major metabolite in human serum/plasma by capillary gas chromatography/negative ion chemical ionization mass spectrometry
29. Biotransformation of pravastatin sodium in humans
30. Comparative pharmacokinetics of lovastatin, simvastatin and pravastatin in humans
31. Disposition of pravastatin sodium, a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects
32. Clinical experience with lovastatin
33. Pharmacokinetic interaction between propranolol and the HMG-CoA reductase inhibitors pravastatin and lovastatin
34. Comparative pharmacokinetics and pharmacodynamics of pravastatin and lovastatin
35. The clinical pharmacology of SQ 31,000 (CS 514) in healthy subjects
36. Pharmacokinetics and pharmacodynamics of pravastatin alone and with cholestyramine in hypercholesterolemia
37. Clinical pharmacology of pravastatin, a selective inhibitor of HMG-CoA reductase
38. Effects of food on pravastatin pharmacokinetics and pharmacodynamics
39. II. Comparative efficacy and safety of pravastatin and cholestyramine alone and combined in patients with hypercholesterolemia
40. Clinical pharmacokinetics and practical applications of simvastatin
41. +-independent multispecific anion transporter mediates active transport of pravastatin into rat liver
42. Mechanism of action and differential pharmacology of pravastatin, a hydrophilic and selective HMG-CoA-reductase inhibitor
43. Lovastatin and simvastatin: The relationship between inhibition of de novo sterol synthesis and active drug concentrations in the liver, spleen and testis in rat
44. Concentrations of pravastatin and lovastatin in cerebrospinal fluid in healthy subjects
45. Single dose pharmacokinetics of pravastatin and metabolites in patients with renal impairment
46. Altered disposition of pravastatin following concomitant drug therapy with cyclosporin A in transplant recipients
47. Comparative pharmacokinetics of pravastatin, an HMG CoA reductase inhibitor, in healthy elderly and young male subjects
48. Excretion of pravastatin, an HMG-CoA reductase inhibitor, in breast milk of lactating women
49. HMG-CoA reductase inhibitors: clinical pharmacology
50. Efficacy and safety of pravastatin in patients with primary hypercholesterolemia II. Once-daily versus twice-daily dosing
51. Effects of lovastatin and pravastatin on sleep efficiency and sleep stages
52. Comparisons of effects of sleep on lovastain and pravastatin in hypercholesterolaemia